A systematic review to identify how the current clinical trials landscape reflects the James Lind Alliance top 10 research priorities for cystic fibrosis

QR Code

A systematic review to identify how the current clinical trials landscape reflects the James Lind Alliance top 10 research priorities for cystic fibrosis

This is a protocol to describe the methodology for a systematic review of clinical trials registries to identify intervention trials in the treatment of CF and map them to priorities for CF research.

Bibliographic Details
Main Authors:	Kalaitzis, I.S., Rowbotham, Nicola J., Smith, S.J., Smyth, A.R.
Format:	Other
Published:	Unpublished 2018
Subjects:	cystic fibrosis systematic review priority setting clinical trial thematic analysis
Online Access:	https://eprints.nottingham.ac.uk/52745/

Similar Items

Working with the patient and clinical community to deliver clinical research in cystic fibrosis. James Lind CF Phase II
by: Smith, S.J., et al.
Published: (2018)

The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and health care providers
by: Rowbotham, Nicola J., et al.
Published: (2017)

Delayed publications of clinical trials in cystic fibrosis
by: Hurley, M.N., et al.
Published: (2011)

Cystic Fibrosis James Lind Alliance Priority Setting Partnership PROTOCOL [5 February 2016]
by: Smyth, Alan R., et al.
Published: (2016)

Cystic Fibrosis James Lind Alliance Priority Setting Partnership PROTOCOL [updated 13 July 2016]
by: Smyth, Alan R., et al.
Published: (2016)

Glutamine supplementation in cystic fibrosis: a randomized placebo-controlled trial
by: Forrester, Doug L., et al.
Published: (2015)

Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis
by: Hurley, M.N., et al.
Published: (2012)

European Cystic Fibrosis Society standards of care: best practice guidelines
by: Smyth, Alan R., et al.
Published: (2014)

Xbox Kinect™ represents high intensity exercise for adults with cystic fibrosis
by: Holmes, H., et al.
Published: (2013)

Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis
by: Smyth, Alan R.
Published: (2015)

Early respiratory bacterial detection and anti-staphylococcal antibiotic prophylaxis in young children with cystic fibrosis
by: Hurley, Matthew, et al.
Published: (2017)

The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: a randomised comparison
by: Prayle, A.P., et al.
Published: (2015)

Understanding the Costs of Care for Cystic Fibrosis: an Analysis by Age and Health State
by: Van Gool, K., et al.
Published: (2013)

Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis
by: Hurley, M.N., et al.
Published: (2012)

Cost-Effectiveness of Carrier Screening for Cystic Fibrosis in Australia
by: Norman, Richard, et al.
Published: (2012)

Measures of body habitus are associated with lung function in adults with cystic fibrosis: a population-based study
by: Forrester, Doug L., et al.
Published: (2013)

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis
by: Langton Hewer, Simon C., et al.
Published: (2014)

Prevention of treatment related adverse effects in cystic fibrosis
by: Jain, Kamini
Published: (2018)

High prevalence of subclass-specific binding and neutralizing antibodies against Clostridium difficile toxins in adult cystic fibrosis sera: possible mode of immunoprotection against symptomatic C. difficile infection
by: Monaghan, Tanya M., et al.
Published: (2017)

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients
by: Elborn, J. Stuart, et al.
Published: (2015)

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients
by: Flume, Patrick, et al.
Published: (2016)

Human Genetics Society of Australasia Position Statement: Population-Based Carrier Screening for Cystic Fibrosis
by: Delatycki, M., et al.
Published: (2014)

Prescribing practices for intravenous aminoglycosides in UK cystic fibrosis clinics: a questionnaire survey
by: Smyth, Alan R., et al.
Published: (2014)

Mitigating the harm caused by Pseudomonas aeruginosa in Cystic Fibrosis
by: Palser, Sally C.
Published: (2024)

Development of a transition readiness scale for young adults with cystic fibrosis: face and content validity
by: Dudman, Lauren, et al.
Published: (2011)

Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease
by: Hussein, Norita, et al.
Published: (2015)

An evaluation of the High Frequency Digit Triplet Test as a screening tool for early detection of hearing loss in individuals with Cystic Fibrosis. Protocol v2.1.
by: Smyth, Alan R., et al.
Published: (2016)

Molecular mechanisms of enhanced expression of the chemokine interleukin 8 (CXCL8) in cystic fibrosis (CF) airway epithelial cells
by: Poghosyan, Anna
Published: (2014)

Scoping review of the literature about family-centred care with caregivers of children with cystic fibrosis
by: Shields, L., et al.
Published: (2013)

Surviving and thriving in the cystic fibrosis lung: contribution of an arginine specific aminopeptidase to sustained infection by Pseudomonas aeruginosa
by: Spencer, Daniella Lucy
Published: (2019)

Lectin-mediated biofilm maturation, quorum sensing and Pseudomonas aeruginosa infections in cystic fibrosis
by: Crusz, S.A.
Published: (2009)

Study of hyperpolarised 3He MRI diffusion on asthma and cystic fibrosis, and development of hyperpolarised 129Xe MRI lung imaging
by: Hardy, Steven M.
Published: (2016)

Identifying research priorities for digital technology in mental healthcare: results of the James Lind Alliance Priority Setting Partnership
by: Hollis, Chris, et al.
Published: (2018)

Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease
by: Hussein, Norita, et al.
Published: (2018)

Rate of improvement of CF life expectancy exceeds that of general population: observational death registration study
by: Hurley, Matthew, et al.
Published: (2014)

Setting priorities for EU healthcare workforce IT skills competence improvement
by: Li, Sisi, et al.
Published: (2017)

The use of magnetic resonance imaging to elucidate the mechanisms of gastrointestinal symptoms and complications in cystic fibrosis
by: Ng, Christabella
Published: (2022)

Identifying priority areas for research into the diagnosis, treatment and prevention of cellulitis (erysipelas): results of a James Lind Alliance Priority Setting Partnership
by: Thomas, K.S., et al.
Published: (2017)

Which outcomes are reported in cellulitis trials?: results of a review of outcomes included in cellulitis trials and a patient priority setting survey
by: Smith, Emma, et al.
Published: (2017)

Priorities for research in miscarriage: a priority setting partnership between people affected by miscarriage and professionals, following the James Lind Alliance methodology
by: Prior, Matthew, et al.
Published: (2017)